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Abstract
We examined expression of protease-activated receptors 2 (PAR2) and characterized their signaling pathways in rabbit
gastric muscle cells. The PAR2 activating peptide SLIGRL (PAR2-AP) stimulated Gq, G13, Gi1, PI hydrolysis, and Rho kinase
activity, and inhibited cAMP formation. Stimulation of PI hydrolysis was partly inhibited in cells expressing PAR2 siRNA, Gaq
or Gai minigene and in cells treated with pertussis toxin, and augmented by expression of dominant negative regulator of G
protein signaling (RGS4(N88S)). Stimulation of Rho kinase activity was abolished by PAR-2 or Ga13 siRNA, and by Ga13
minigene. PAR2-AP induced a biphasic contraction; initial contraction was selectively blocked by the inhibitor of PI
hydrolysis (U73122) or MLC kinase (ML-9), whereas sustained contraction was selectively blocked by the Rho kinase inhibitor
(Y27632). PAR2-AP induced phosphorylation of MLC20, MYPT1 but not CPI-17. PAR2-AP also caused a decrease in the
association of NF-kB and PKA catalytic subunit: the effect of PAR2-AP was blocked by PAR2 siRNA or phosphorylation-
deficient RhoA (RhoA(S188A)). PAR2-AP-induced degradation of IkBa and activation of NF-kB were abolished by the
blockade of RhoA activity by Clostridium botulinum C3 exoenzyme suggesting RhoA-dependent activation of NF-kB. PAR2-
AP-stimulated Rho kinase activity was significantly augmented by the inhibitors of PKA (myristoylated PKI), IKK2 (IKKIV) or
NF-kB (MG132), and in cells expressing dominant negative mutants of IKK (IKK(K44A), IkBa (IkBa (S32A/S36A)) or
RhoA(S188A), suggesting feedback inhibition of Rho kinase activity via PKA derived from NF-kB pathway. PAR2-AP induced
phosphorylation of RhoA and the phosphorylation was attenuated in cells expressing phosphorylation-deficient
RhoA(S188A). Our results identified signaling pathways activated by PAR2 to mediate smooth muscle contraction and a
novel pathway for feedback inhibition of PAR2-stimulated RhoA. The pathway involves activation of the NF-kB to release
catalytic subunit of PKA from its binding to IkBa and phosphorylation of RhoA at Ser188.
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Introduction
Protease-activated receptors (PARs) comprise a family of G
protein-coupled receptors with a unique activation mechanism
involving proteolytic cleavage of the extracellular N-terminus
domain of the receptor to expose a new built-in N-terminus part of
the receptor that acts as a ligand (also known as ‘‘tethered ligand’’).
Molecular cloning studies have identified four PARs and these are
activated by a large number of proteases [1]. Physiologically
thrombin activates PAR1, PAR3 and PAR4, whereas trypsin
activates PAR2 [1–3]. Each PAR has a unique N-terminal
tethered ligand sequence and binding of tethered ligand to the
extracellular loop of the receptor results in conformational changes
that permit interaction of receptors with heterotrimeric G proteins
and leads to activation of a substantial network of signaling
pathways. Receptor-specific, synthetic peptides as short as 5–6
amino acids, corresponding to the amino acid sequence of the
exposed tethered ligand, known as PAR-activating peptides (PAR-
AP) mimic the effect of the proteases independent of the
proteolytic cleavage of the receptor [4].
PARs are located in several cell types and play an important
role in many physiological functions. The gastrointestinal (GI)
tract, of all the body systems, is exposed to the widest array of
proteases in both normal situations and during diseases [1,3,5–7].
PARs, especially PAR1 and PAR2 are abundantly expressed
throughout the GI system [7]. PAR2 which is activated by trypsin,
tryptase, and other endogenous and exogenous proteases play an
important role in several gastrointestinal functions [5,6,8–11].
PAR2s are present in spinal sensory afferents co-localized with
neuropeptides, substance P and calcitonin gene-related peptide
and activation of PARs causes release of these neuropeptides,
suggesting a role in nociception [12]. PAR2s are also expressed
within both excitatory and inhibitory motor neurons suggesting a
role in neuronal transmission to regulate GI function such as
mucosal protection, secretion and motility [8].
The role of PAR2 in GI motility is complex, and varies with
species and tissue. In vivo studies have demonstrated that
activation of PAR2 enhances GI transit [13]. In longitudinal
strips of mouse gastric fundus, activation of PAR2 causes biphasic
responses, relaxation followed by contraction [14], whereas PAR2
activation in rat duodenal longitudinal muscle causes only a small
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contraction [15]. In colon the effects of PAR2 on circular and
longitudinal muscle are distinct: a concentration-dependent
reduction of the spontaneous phasic contraction in the circular
muscle and contractile effects in the longitudinal muscle [16].
Thus, the effect of PAR activation on gut motility is diverse, which
include relaxation, contraction, or biphasic response of relaxation
followed by contraction and this could be dependent on whether
the activated receptor is present predominantly on smooth muscle
cells or enteric neurons. Transmitters released from the enteric
neurons, or release of endogenous prostanoids in response to PAR
activation, in turn, modulate the intrinsic electrical and mechan-
ical activities of the smooth muscle. Expression of PAR2 receptors
and the mechanism underlying their effects on smooth muscle cells
of the gastrointestinal tract are not known.
The present study focused on characterizing expression of
PAR2 and the signaling pathways to which these receptors are
coupled in freshly dispersed and cultured smooth muscle cells of
rabbit stomach. The small synthetic peptide SLIGRL, corre-
sponding to tethered ligand sequences, was used to selectively
activate PAR2 and to identify the signaling pathways activated by
PAR2. Our results demonstrate that PAR2 are coupled to Gq, Gi
and G13, and stimulation of PI hydrolysis and RhoA/Rho kinase
activity to induce muscle contraction. A novel cAMP-independent
PKA pathway for feedback inhibition of PAR2-stimulated RhoA
was demonstrated involving activation of NF-kB and release of
PKA from its binding to IkBa complex leading to phosphorylation
of RhoA at Ser188.
Materials and Methods
PAR2-activating peptide (PAR2-AP, SLIGRL) was obtained
from Bachem, Torrance, CA; [125I]cAMP, [c-32P]ATP, [32P]Pi,
[35S]GTPcS, and [3H]myo-inositol were obtained from Perkin
Elmer Life Sciences, Boston, MA; Collagenase CLS type II and
soybean trypsin inhibitor were obtained from Worthington,
Freehold, NJ; Western blotting, Dowex AG-168 resin (100–200
mesh in formate form), chromatography material and protein
assay kit from Bio-Rad Laboratories, Hercules, CA; antibodies to
Gaq, Gai1, Gai2, Gai3, Ga12, Ga13, Gas, phospho-specific MYPT1
(Thr696), MLC20 (Ser
19) and CPI-17 (Thr38), Rho kinase, PKA
catalytic subunit, IKK2(ser177/181), IkBa, and p65 subunit were
from Santa Cruz Biotechnology, Santa Cruz, CA; myelin basic
protein (MBP) was from Upstate Biotechnology; ML-9 was from
Biomol Research Laboratories, Plymouth Meeting, PA; bisindo-
lylmaleimide, Y27632, pertussis toxin, cAMP; Clostridium botulinum
C3 exoenzyme, IKK-2 Inhibitor IV (IKK IV), MG-132,
myristoylated PKI and U73122 were from Calbiochem, La Jolla,
CA; RNAqueousTM kit was from Ambion, Austin, TX; Effectene
Transfection Reagent, QIAEXHII Gel extraction Kit and
QIAprepHSpin Miniprep Kit were from Germantown, MD;
PCR reagents were from Applied Biosystems, Roche; Super-
ScriptTM II Reverse Transcriptese and TOPO TA CloningH Kit
Dual Promoter were from Invitrogen, Grand Island, NY; EcoR I
was from New England Bio Labs, Ipswich, MA; All other
chemicals were from Sigma, St. Louis, MO.
New Zealand white rabbits (weight: 4–5 lbs) were purchased
from RSI Biotechnology Clemmons, NC and all procedures were
conducted in accordance with the Institutional Animal Care and
Use Committee of the Virginia Commonwealth University.
Preparation of dispersed gastric smooth muscle cells
The antrum was separated from the rest of the stomach and the
mucosal layer was removed by sharp dissection. Smooth muscle
cells from the circular muscle layer of the antrum were isolated by
sequential enzymatic digestion of muscle strips, filtration, and
centrifugation as described previously [17,18]. The antrum was
cut into thin slices using a Stadie-Riggs tissue slicer and then the
slices were incubated for 30 min in a smooth muscle buffer (NaCl
120 mM, KCl 4 mM, KH2PO4 2.6 mM, CaCl2 2.0 mM, MgCl2
0.6 mM, HEPES (N-2-hydroxyethylpiperazine-N’ 2-ethanesulfo-
nic acid) 25 mM, glucose 14 mM, and essential amino acid
mixture 2.1% (pH7.4)) at 31uC containing 0.1% collagenase
(300 U/ml) and 0.01% soybean trypsin inhibitor (w/v). The partly
digested tissues were washed twice with 50-ml of collagenase-free
smooth muscle buffer and the muscle cells were allowed to disperse
spontaneously for 30 min in collagenase-free medium. Cells were
harvested by filtration through 500 mm Nitex and centrifuged
twice at 350 g for 10 min to eliminate broken cells and organelles.
Dispersed muscle cells isolated from the antrum were
resuspended in DMEM containing penicillin (200 U/ml), strep-
tomycin (200 mg/ml), gentamycin (100 mg/ml), amphotericin B
(2.5 mg/ml) and 10% fetal bovine serum (DMEM-10). The muscle
cells were plated at a concentration of 56105 cells/ml and
incubated at 37uC in a CO2 incubator. DMEM-10 medium was
replaced every three days for 2–3 weeks until confluence was
attained. All experiments were done on cells in the first passage
[19].
Transfection of dominant negative mutants, minigene
constructs and siRNA into cultured smooth muscle cells
Wild type RGS4, dominant negative RGS4 (RGS4[N88S]),
IKK2 (IKK2[K44A]), IkB (IkBa[S32A/S36A]), and phosphory-
lation-site deficient RhoA (RhoA[S188A]) were subcloned into the
multiple cloning site (EcoR I) of the eukaryotic expression vector
pcDNA3. Recombinant plasmid DNAs were transiently transfect-
ed into the muscle in primary culture using Effectene Transfection
Reagent (QIAGEN) for 48 h. Cells were co-transfected with 2 mg
of pcDNA3 vector and 1 mg of pGreen Lantern-1 DNA.
Transfection efficiency was monitored by the expression of the
green fluorescent protein using FITC filters. Control cells were
transfected with vector alone [19,20]. Analysis by fluorescence
microscopy showed that approximately 80% of the cells were
transfected.
The cDNA sequences encoding the last COOH-terminal 11
amino acids of mouse Gaq, Ga12, and Ga13, and human Gai were
amplified by PCR and verified by DNA sequencing as previously
described [21–23]. The 59-end of sense primers contained a
BamHI site followed by the ribosome binding consensus sequence
(59-GCCGCCACC-39), a methionine (ATG) start code, and a
glycine (GGA) to protect the ribosome binding site during
translation and the nascent peptide against proteolytic degrada-
tion. An EcoRI site was synthesized at the 59-end of the antisense
primers immediately after the stop codon (TGA). The purified
PCR products were subcloned into the mammalian expression
vector pcDNA3.1(+). The oligonucleotide sequence corresponding
to the COOH-terminal 11 amino acid residuals of Gai in random
order was synthesized and ligated into pcDNA3.1(+) as a control
minigene. All Ga minigene constructs used for transfection
experiments were purified with an endotoxin-free maxiprep kit
(Qiagen) following the manufacturing protocol.
The siRNAs (small interfering RNA) for PAR-2, Gaq/11 and
Ga13 with lowest predicted off-target potential and 100%
homology with the conserved sequences based on human, rat
and mouse sequences were selected and obtained from Life
Technologies (Grand Island, NY). PAR-2 (ID#s453494): sense: 59
CCUCCUCUCUGUCAUCUGGTT 39, antisense: 59 CCA-
GAUGACAGAGAGGAGGTC39; Gaq/11 (ID# s5862): sense:
59 GCAUCAUCGAGUACCCUUUTT 39, antisense: 59
Signaling by PAR2 Receptors in Smooth Muscle
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AAAGGGUACUCGAUGAUGCCG 39; and Ga13 (ID#20990):
sense: 59 GCAACGUGAUCAAAGGUAUTT 39, antisense: 59
AUACCUUUGAUCACGUUGCTG39. siRNA transfection effi-
ciency assays were performed with varying concentrations of
siRNA (5–50 nM) and it was determined that 40 nM siRNA
provided optimal transfection efficiency (data not shown). Non-
specific siRNAs were used to determine the efficiency of siRNA.
The siRNA transfection was performed using siRNA transfection
reagent and siRNA transfection medium according to the
manufacturer’s instructions.
Identification of G proteins coupled to PAR2 receptor
G proteins selectively activated by PAR2-AP were identified
from the increase in Ga binding to the [35S]GTPcS (59-O-3-
thiotriphosphate) using the method of Okamoto et al as described
previously [21,24]. Ten ml of muscle cell suspension (36106 cells/
ml) were homogenized in 20 mM HPES medium (pH 7.4)
containing 2 mM MgCl2, 1 mM EDTA and 2 mM DTT. After
centrifugation at 30,000 g for 15 min, the crude membranes were
solubilized for 60 min at 4 uC in 20 mMHEPES medium (pH 7.4)
containing 2 mM EDTA, 240 mM NaCl, 0.5% CHAPS (3-[(3-
cholamidopropyl) dimethylammonio]-1-pro-panesulfonate),
2 mM PMSF, 20 mg/ml aprotinin, and 20 mM leupetin. The
membranes were incubated for 20 min at 37uC with 60 nM
[35S]GTPgS in the presence or absence of PAR2-AP in a solution
containing 10 mM HEPES (pH 7.4), 100 mM EDTA and 10 mM
MgCl2. The reaction was terminated with 10 volumes of 100 mM
of Tris-HCl medium (pH 8.0) containing 10 mM MgCl2, 10 mM
NaCl and 10 mM GTP, and the mixture was placed in wells
precoated with specific antibodies to Gaq, Gai1, Gai2, Gai3, Ga12,
Ga13, and Gas. Coating with G protein antibodies (1:1000) was
done after the wells were first coated with anti-rabbit IgG (1:1000)
for 2 h on ice. After incubation for 2 h on ice, the wells were
washed three times with phosphate buffer saline solution (PBS)
containing 0.05% Tween-20 and the radioactivity from each well
was counted by liquid scintillation. The amount of [35S]GTPgS
bound to the activated Ga subunit was expressed as counts per
minute (cpm) per milligram of protein.
Assay for Phosphoinositide (PI) hydrolysis
Total inositol phosphates were measured by anion exchange
chromatography using the method of Berridge et al [25] as
described previously [19]. Ten ml of cell suspension (26106 cells/
ml) were labelled with myo-[3H] inositol (15 mCi/ml) for 3 h at
31uC. Then cells were centrifuged at 350 g for 10 min to move
excess [3H]inositol and resuspended in 10 ml of fresh medium.
PAR2-AP was added to 0.5 ml of cell suspension and the mixture
was incubated in a shaking water bath for 1 min. Cultured smooth
muscle cells were labelled with [3H]myo-inositols (0.5 mCi/ml) for
24 h in inositol-free DMEM medium. The cultures were washed
with phosphate-buffered saline (PBS) and treated with PAR2-AP
for 1 min in HEPES medium (pH 7.4). The reaction was
terminated by the addition of chloform:methanol:HCl (50:100:1
v/v/v). After chloroform (340 ml) and water (340 ml) were added,
the samples were vortexed and the phase was separated by
centrifugation at 1000 g for 15 min. The upper aqueous phase was
applied to a column containing 1 ml of 1:1 slurry of Dowex AG-1
X8 resin (100–200 mesh in formate form) and distilled water.
Total inositol phosphates were eluted with 6 ml of 0.8 M
ammonium formate-0.1 M formic acid. The eluates were collected
into scintillation vials and counted in gel phase after addition of
10 ml of scintillant. The results were expressed as counts per
minute per mg protein.
Assay for Rho Kinase activity
Rho kinase activity was measured by an immunokinase assay as
previously described [21]. Cultured cells were washed one time
with PBS, and then were lysed with lysis buffer containing 50 mM
Tris-HCl (pH 7.5),150 mM NaCl, 0.1% SDS, 0.5% sodium
deoxycholate, 1% NP-40, 10 mM sodium pyrophosphate, and
protease inhibitor cocktail (2 ml/ml, BD Biosciences). The
homogenates were centrifuged at 10,000 rpm for 10 min at 4
uC. The supernatant containing cytosolic protein was transferred
to a fresh tube and 5 ml of Rho kinase antibody was added to each
tube and incubated for 2 h at 4 uC followed by overnight
incubation at 4 uC with Protein A/G. The pellets were re-
suspended in 50 ml of kinase buffer containing 100 mM Tris-HCl
(pH 7.4), 1 M KCl, 50 mM MgCl2, 10 mM EDTA, and 1 mM
DTT. Twenty microliters of Rho kinase immunoprecipitates were
added to the reaction mixture containing 100 mM Tris-HCl
(pH 7.4), 1 M KCl, 50 mM MgCl2, 1 mM DTT, 1 mM ATP,
and 10 mCi of [g-32P]ATP (3,000 Ci/mol) along with 5 mg of
myelin basic protein, followed by incubation for 15 min at 37 uC.
Phosphorylation of myelin basic protein was absorbed onto
phosphocellulose disks, and free radioactivity was removed by
washing 3 times with 75 mM H3PO4. The amount of radioactivity
on the disks was measured by liquid scintillation. The results are
expressed as counts per milligram protein per minute.
Assay for adenylyl cyclase activity
Adenylyl cyclase activity was measured by the formation of
cAMP in response to agonists by radioimmunoassay using
[125I]cAMP [18,21]. One ml (36106 cells/ml) of cell suspension
was treated for 60 s with forskolin (10 mM) in the presence of
100 mM isobutylmethyl xanthine, either alone or in combination
with PAR2-AP (1 mM). The reaction was terminated with cold 6%
trichloroacetic acid (v/v) and vortexed vigorously. After centrifu-
gation, the supernatants were extracted three times with water-
saturated diethyl ether to remove the tricholoroacetic acid and the
samples were then lyophilized and frozen at –20uC. The samples
were reconstituted for radioimmunoassay in 50 ml of 50 mM
sodium acetate (pH 6.2) and acetylated with triethylamine/acetic
anhydride (2:1 v/v) for 30 min. Cyclic AMP was measured in
duplicates using 100 ml aliquots and the results were computed
from a standard curve using the Prizm@. The results are
expressed as pmol of cAMP/mg protein.
Phosphorylation of RhoA
Protein phosphorylation was determined from the amount of
32P incorporated into each protein after immunoprecipitation with
specific antibody to RhoA as previously described [26]. Freshly
dispersed cells were incubated with [32P] orthophosphate for 4 h.
One milliliter of samples was incubated with PAR2-AP (1 mM) for
10 min and the reaction was terminated by rapid centrifugation.
The pellet was homogenized in lysis buffer containing 50 mM
Tris-HCl (pH 7.5),150 mM NaCl, 0.1% SDS, 0.5% sodium
deoxycholate, 1% NP-40, 10 mM sodium pyrophosphate, and
protease inhibitor cocktail (2 ml/ml). Cell lysates were separated by
centrifugation at 13,000 g for 10 min at 4 uC, precleared with
40 ml of protein A-Sepharose, and incubated with RhoA antibody
for 2 h at 4 uC and with 40 ml of protein A-Sepharose for another
one hour. The immunoprecipitates were extracted with Laemmli
sample buffer, boiled for 5 min, and separated by electrophoresis
on SDS-PAGE. After transfer to nitrocellulose membranes
[32P]RhoA was visualized by autoradiography.
Signaling by PAR2 Receptors in Smooth Muscle
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Western blot analysis
Phosphorylation of MLC20, MYPT1, CPI-17, IKK2, and the
p65 subunit of NF-kB was measured using phospho-specific
antibodies and the degradation of IkB was measured using IkB
antibody (1:1000) as described previously [19]. One milliliter of
cell suspension (26106 cell/ml) was treated with PAR2-AP (1 mM)
and solubilized on ice for one hour in medium containing 20 mM
Tri-HCl (pH 8.0), 1 mM DTT, 100 mM NaCl, 0.5% sodium
dodecyl sulfate, 0.75% deoxycholate, 1 mM PMSF, 10 mg/ml of
leupeptin and 100 mg/ml of aprotinin. The proteins were resolved
by SDS/PAGE and electrophoretically transferred onto nitrocel-
lulose membranes. The membranes were incubated for 12 h with
phospho-specific antibodies to MLC20 (Ser
19), MYPT1 (Thr696),
CPI-17 (Thr38), IKK2(ser177/181), p65 subunit (Ser536), IkBa or
NF-kB, and then for 1 h with horse-radish peroxidase-conjugated
secondary antibody (1:2000). The protein bands were identified by
enhanced chemiluminescence reagent.
Measurement of contraction in dispersed smooth muscle
cells
Contraction in freshly dispersed gastric circular smooth muscle
cells was determined by scanning micrometry as previously
described [19,27]. An aliquot (0.4 ml) of cells containing
approximately 104 cells/ml was treated with 100 ml of medium
containing various concentrations of PAR2-AP for different time
periods (30 s to 10 min) and the reaction was terminated with 1%
acrolein at a final concentration of 0.1%. The composition of the
medium was 120 mM NaCl, 4 mM KCl, 2.6 mM KH2PO4,
0.6 mM MgCl2, 25 mM HEPES, 14 mM glucose, 2 mM CaCl2,
and 2.1% Eagle’s essential amino acid mixture. Concentration-
response curves for PAR2-AP were constructed for the peak
contraction, which occurred at 30 s after addition of PAR2-AP.
The mean lengths of 50 muscle cells treated with PAR2-AP were
measured by scanning micrometry and compared with the mean
lengths of untreated cells. The contractile response was expressed
as the percent decrease in mean cell length from control cell
length.
Statistical analysis
The results were expressed as means 6 S.E. of n experiments. P
values were determined by an unpaired, two-tailed Student’s t test
when comparing two samples, by one-way ANOVA with a
Dunnett post hoc test when comparing more than two samples to
a control, or by one-way ANOVA with a Tukey post hoc test
when comparing multiple samples using GraphPad InStat
software (Version 3.06 for Windows, San Diego, CA, USA). Each
experiment was done on cells obtained from different animals. A
probability of p,0.05 was considered significant.
Results
Expression of PAR2 and G protein activation by PAR2-AP
in smooth muscle
Western blot analysis of homogenates derived from rabbit
gastric smooth muscle cells using antibodies to PAR2 (1:1000
dilution) (Santa Cruz, CA; sc-8206) demonstrated presence of
PAR2 in smooth muscle (Fig. 1A). The specificity of antibody was
determined using immunizing peptide (Santa Cruz, CA; sc-8206
p) blocking experiment (data not shown) and validated by PAR2
siRNA experiment. Transfection of cells with PAR2-specific
siRNA for 48 h greatly suppressed the expression of PAR2 (Fig.
1A).
Studies in various tissues and cell lines suggest that PAR2 are
coupled to both pertussis toxin (PTx)-sensitive (Gi) and -insensitive
(Gq, G12/G13) G proteins, but the specific Gi isoforms and G12 and
G13 proteins coupled to PAR2 have not been identified [4,7].
Addition of PAR2-AP caused a 2.3-, 3.1-, 4.8-, and 3.2-fold
(P,0.01) increase in the binding of Gai1, Gai2, Gaq, and Ga13,
respectively (Fig. 1B). PAR2-AP did not cause significant increase
in the binding to Gai3, Ga12, and Gas (7610% to 1168% increase
above basal levels). These results suggest that PAR2 is coupled to
Gi1, Gi2, Gq and G13.
Figure 1. (A) Expression of PAR2 in rabbit gastric smooth muscle cells.
Western blot was performed on homogenates prepared from cultured
gastric smooth muscle cells from rabbit. Lysates were prepared from
control cells and cells transfected with PAR2-specific siRNA and proteins
were resolved by SDS-polyacrylamide gel electrophoresis, transferred to
nitrocellulose membrane, and probed with specific antibodies to PAR2
(1:1000). Immunoreactive bands for PAR2 was detected by enhanced
chemiluminescence. Suppression of PAR2 expression in cells transfect-
ed with PAR2 siRNA suggests that selectivity of antibodies and validity
of siRNA transfection. (B) Activation of G proteins PAR2-AP in gastric
smooth muscle cells. Membranes isolated from freshly dispersed
smooth muscle cells were incubated with 35S-labeled guanosine 5-O-
(3-thiotriphosphate) ([35S]GTPgS) in the presence or absence of PAR2-
activating peptide (PAR2-AP) (1 mM) for 20 min. Aliquots were added to
wells coated with Gaq, Gai1, Gai2, Gai3, Gas, Ga12 or Ga13 for 2 h and
bound radioactivity was measured. Results are expressed as cpm/mg
protein. PAR2-AP caused a significant increase in the binding of [35S]-
GTPgS-Ga complexes to wells coated with Gai1 and Gai2, Gaq, and Ga13.
PAR2-AP did not cause significant increase in the binding to Gai3, Ga12,
and Gas (7610% to 1168% increase above basal levels). Values are
means 6 S.E. of four experiments. ** Significant increase in G protein
activation (P,0.001).
doi:10.1371/journal.pone.0066743.g001
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Stimulation of phosphoinositide (PI)-specific PLC activity
(PI hydrolysis) by PAR2-AP
PAR2-AP stimulated PI hydrolysis in a concentration-depen-
dent fashion with an EC50 of 2 nM and maximal increase of
423646% (P,0.001) above basal levels (basal activity
520666 cpm/mg protein) (Fig. 2A). Treatment of cells with
pertussis toxin (PTx, 200 ng/ml) for 1 h partially inhibited
(3365%% inhibition, P,0.01) PI hydrolysis in response to PAR2-
AP suggesting that PAR2 stimulated PI hydrolysis was mediated
by both PTx-sensitive (Gi) and -insensitive (Gq) G proteins (Fig.
2B). Stimulation of PI hydrolysis in response to PAR2-AP was
abolished by the selective PI hydrolysis inhibitor, U73122 (10 mM)
(Fig. 2B). Treatment of cells with PTx alone (5636102 cpm/mg
protein) or U73122 alone (485686 cpm/mg protein) had no effect
on basal PI hydrolysis.
Treatment of cells with trypsin (1 mM), which activates PAR2
also stimulated PI hydrolysis (26536302 cpm/mg protein above
basal levels of 439668 cpm/mg protein) similar to that obtained
with PAR2-AP. Evidence for the involvement of PAR2 receptors
in the stimulation of PI hydrolysis in response to PAR2-AP was
obtained using PAR2-specific siRNA. Increase in PI hydrolysis in
response to PAR2-AP was significantly inhibited (8366%,
p,0.001) in cells transfected with PAR2 siRNA (Fig. 2C).
The involvement of Gq and Gi in mediating PI hydrolysis in
response to PAR2-AP was corroborated in experiments using Ga
minigenes in cultured smooth muscle cells. Expression of Ga
minigenes was confirmed by RT-PCR using primers correspond-
ing to Ga insert and vector. The primers for the Ga minigenes
amplified a PCR product of 434 bp when Ga insert are present
(data not shown). The synthetic peptide corresponding to the
COOH terminus of Ga subunits selectively antagonized G protein
activation by blocking receptor-G protein interaction [21].
Previous studies in smooth muscle have shown that expression of
minigene plasmid constructs that encode COOH-terminal peptide
sequence of Gai and Gaq selectively blocked Gi and Gq activation,
respectively [21-23]. A minigene containing Ga in random order
was expressed as a control. Transfection of Ga minigenes had no
effect on the expression of Gaq and Gai levels (Fig. 2D). PAR2-AP
(1 mM) induced PI hydrolysis (, 5-fold) in cultured smooth muscle
cells was closely similar to stimulated PI hydrolysis in freshly
dispersed smooth muscle cells. Expression of Gaq minigene or Gai
minigene partially inhibited PI hydrolysis in response to PAR2-AP
(6265% inhibition and 4564% inhibition, respectively, P,0.01)
(Fig. 2D). Co-expression of Gaq and Gai minigenes or treatment of
cells expressing Gaq minigene with PTx additively inhibited PI
hydrolysis in response to PAR2-AP (9366% and 9067%
inhibition, respectively) (Fig. 2D). It is worth noting that the
inhibition of PAR2-AP-induced PI hydrolysis in cultured smooth
muscle cells expressing Gai minigene was closely similar to
inhibition of PI hydrolysis by PTx in freshly dispersed muscle cells.
Expression of control minigene (random minigene) had no effect
on PI hydrolysis in response to PAR2-AP (27626568 above basal
levels of 456676 cpm/mg protein). Transfection of cultured
muscle cells with Gaq siRNA also partially inhibited PAR2-AP
stimulated PI hydrolysis (15396203 cpm/mg protein above basal
levels of 348662 cpm/mg protein; 5364% inhibition compared
to control response). Treatment of cells transfected with Gaq
siRNA and PTx blocked PI hydrolysis (536678 cpm/mg protein
above basal levels of 382665 cpm/mg protein). The results
corroborate that PI hydrolysis by PAR2 was mediated by both Gq
and Gi.
Further evidence for the involvement of Gq proteins in the
regulation of PI hydrolysis by PAR2-AP was obtained in cultured
muscle cells. The strength and duration of Ga-GTP signaling are
regulated by a family of GTPase-activating proteins known as
regulators of G protein signaling (RGS). Previous studies have
shown that Gaq-GTPase activity is regulated by RGS4 in smooth
muscle cells [20]. To examine whether the activation of PI
hydrolysis by PAR2-AP is regulated by RGS4, we overexpressed
dominant negative RGS4(N88S) that lacks the ability to stimulate
Ga-GTPase activity in cultured muscle cells. PI hydrolysis in
response to PAR2-AP was significantly augmented (7565%
increase) in cells overexpressing RGS4(N88S) (Fig. 2E). In
contrast, PI hydrolysis in response to PAR2-AP was significantly
attenuated (4264% inhibition) in cells overexpressing wild type
RGS4 (Fig. 2E). The pattern implied that PAR2-induced PI
hydrolysis was mediated by Gaq-dependent activation of PLC-b1
and augmented by inactivation of RGS4.
Inhibition of adenylyl cyclase by PAR2-AP
Freshly dispersed smooth muscle cells were used to examine the
ability of Gi-coupled PAR2 to inhibit forskolin-stimulated cAMP
formation. Treatment of muscle cells with forskolin (10 mM) for 10
min significantly increased cAMP formation (22.161.86 pmol/mg
protein above basal level of 2.860.5 pmol/mg protein) in the
presence of 100 mM isobutyl methyl xanthine. PAR2-AP (1 mM)
inhibited forskolin-stimulated cAMP formation by 6163% (Fig. 3).
Preincubation of muscle cells with PTx (200 ng/ml) for 1 h
significantly attenuated the inhibitory effect of PAR2-AP (1562%
inhibition of forskolin stimulated cAMP formation) (Fig. 3). The
results are consistent with the activation of Gi2 and Gi3 by PAR2-
AP. Treatment of cells with PAR2-AP alone had no significant
effect on cAMP levels (2.660.4 pmol/mg protein in the presence
of PAR2-AP versus 2.860.5 pmol/mg protein basal levels) (Fig.
3).
Activation of Rho kinase by PAR2-AP
In freshly dispersed smooth muscle cells PAR2-AP stimulated
Rho kinase activity by 152612% above basal levels (basal levels:
33636587 cpm/mg protein) (Fig. 4A). The specificity of the
immunokinase activity was determined using a selective inhibitor
of Rho kinase (Y27632, 1 mM) (Fig. 4A). Treatment of cells with
Y27632 (1 mM) alone had no effect on basal Rho kinase activity
(30256425 cpm/mg protein).
PAR2-AP also stimulated Rho kinase activity in cultured
smooth muscle cells (164613% increase) that was not significantly
different from the response in freshly dispersed muscle cells.
Overexpression of dominant negative RhoA (RhoA[T19N]) in
cultured muscle cells significantly inhibited Rho kinase activity in
response to PAR2-AP (Fig. 4B), suggesting activation of Rho
kinase is downstream of RhoA. Evidence for the involvement of
G13 in PAR2 mediated Rho kinase activity was obtained by
expression of Ga minigenes in cultured smooth muscle cells.
Expression of Ga12 or Ga13 levels was not altered by transfection
of Ga minigenes (Fig. 4C). Expression of the Ga13 minigene
abolished (6464% inhibition; P,0.01) Rho kinase activation in
response to PAR2-AP, whereas expression of the Ga12 minigene
had no effect (Fig. 4C), Treatment of smooth muscle cells with
PAR1-AP also stimulated Rho kinase activity (121616% above
basal levels of 34256502 cpm/mg protein). The response to
PAR1-AP was blocked by the expression of the Ga12 minigene
(7268% inhibition; P,0.01), but not by the expression of the
Ga13 minigene (864% inhibition). These results suggest that
PAR2-stimulated Rho kinase activity is mediated via G13 and
consistent with selective activation of G13 but not G12 by PAR2-
AP.
Further evidence for the involvement of PAR2 and Ga13 in the
stimulation of Rho kinase activity in response to PAR2-AP was
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obtained using PAR2-specific and Ga13-specific siRNA. Increase
in Rho kinase activity in response to PAR2-AP was significantly
inhibited in cells transfected with PAR2 siRNA (7265%
inhibition, p,0.001) or Ga13 siRNA (6367% inhibition,
p,0.001) (Fig. 4D).
Figure 2. Stimulation of PI hydrolysis by PAR2-AP via Gai and Gaq proteins. (A) Concentration-dependent stimulation of PI hydrolysis PAR2-
AP. Freshly dispersed muscle cells labelled with myo-2-[3H]inositol were incubated with different concentrations of PAR2-AP for 60 s. Total [3H]inositol
phosphates were separated by ion-exchange chromatography. Results are expressed as total [3H]inositol phosphate formation in cpm/mg protein
above basal levels (basal levels: 520666 cpm/mg protein). (B) Selective inhibition of PAR2-AP-stimulated PI hydrolysis by pertussis toxin (PTx).
Dispersed muscle cells labelled with myo-2-[3H]inositol were incubated for 10 min with U73122 (10 mM) or with PTx (200 ng/ml) for 60 min, and then
PAR2-AP (1 mM) for 60 s. Treatment of cells with PTx (5636102 cpm/mg protein) or U73122 (485686 cpm/mg protein) alone had no effect on basal
PI hydrolysis. (C) Inhibition of PAR2-AP-stimulated PI hydrolysis by PAR2 siRNA. Control muscle cells and cells transfected with PAR2-specific siRNA
were labelled with myo-2-[3H]inositol and then treated with PAR2-AP (1 mM) for 60 s. Inset: expression of PAR2 in control cells (lane 1) and cells
transfected with PAR2 siRNA (lane 2) was measured by western blot using antibody to PAR2 (1:1000). (D) Inhibition of PAR2-AP-stimulated PI
hydrolysis by Gaq minigene, Gai minigene or both. Cultured gastric muscle cells labelled with myo-2-[
3H]inositol and expressing Gaq minigene, Gai
minigene, both Gaq and Gai minigenes, or control vector were treated with PAR2-AP (1 mM) for 60 s. In some experiments cells transfected with Gaq
minigene were treated with PTx (200 ng/ml) for 60 min. Inset: expression of Gaq and Gai in control cells (lane 1), cells transfected with Gaq minigene
(lane 2) or Gai minigene (lane 3) was measured by western blot using antibody to Gaq (1: 1000) or a common antibody to Gai (1:2000). (E) Regulation
of PAR2-AP-stimulated PI hydrolysis by regulator of G protein signaling 4 (RGS4). Cultured gastric muscle cells labelled with myo-2-[3H]inositol and
overexpressing wild type RGS4, dominant negative RGS4 (RGS4[N88S]), or vector alone were treated with PAR2-AP (1 mM) for 60 s. Results are
expressed as total [3H]inositol phosphate formation in cpm/mg protein. Values are means 6 S.E. of four experiments. ** Significant inhibition from
control response to PAR2-AP (P,0.001); ## significant increase from control response to PAR2-AP (P,0.01).
doi:10.1371/journal.pone.0066743.g002
Signaling by PAR2 Receptors in Smooth Muscle
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e66743
Contraction induced by PAR2-AP in smooth muscle
Consistent with its ability to stimulate PI hydrolysis and Rho
kinase activity, PAR2-AP caused contraction of dispersed gastric
smooth muscle cells and the contraction was characterized by an
initial transient phase followed by a sustained phase (Fig. 5A). Both
initial and sustained contraction induced by PAR2-AP was
concentration-dependent with an EC50 of 1 nM and 6 nM,
respectively (Fig. 5B). Maximal initial contraction induced by
PAR2-AP (3263% decrease in cell length from a control cell
length of 10563 mm) was similar to that elicited by other
contractile agonists, such as acetylcholine (3163% decrease in
cell length), cholecystokinin (2962% decrease in cell length) or 5-
hydroxytryptamine (3064% decrease in cell length).
MLC20 phosphorylation, measured using phospho-specific
antibody (MLC20 Ser
19), by PAR2-AP was rapid (within 30 s)
and sustained (10 min) closely paralleling the biphasic nature of
contraction (Fig. 5C).
Pathways mediating contraction induced by PAR2-AP
Initial (30 s) contraction by PAR2-AP was abolished by the
PLC-b inhibitor U73122 (10 mM) and the MLC kinase inhibitor
ML-9 (10 mM) (Fig. 5D). Pretreatment of muscle cells with PTx
(200 ng/ml) for 1 h partly inhibited initial contraction induced by
PAR2-AP (Fig. 5D). The partial inhibition of contraction by PTx
implied participation of both Gq and Gi in stimulation of PI
hydrolysis and the results are consistent with the PAR2-AP-
induced activation of PI hydrolysis by both Gq and Gi proteins and
selective inhibition of PI hydrolysis by PTx. Initial contraction
induced by PAR2-AP was not affected by the PKC inhibitor
bisindolylmaleimide (1 mM) or the Rho kinase inhibitor Y27632
(1 mM) (Fig. 5D).
Sustained contraction by PAR2-AP, however, was preferentially
blocked by the Rho kinase inhibitor Y27632 (1 mM) (Fig. 5E), but
not by U73122, ML-9 or bisindolylmaleimide (Fig. 5E). Treatment
of cells with PAR2-AP for 10 min also induced MYPT1
phosphorylation at Thr696 (Fig. 5C).
Activation of nuclear factor NF-kB pathway by PAR2-AP
NF-kB is activated by a variety of stimuli, cytokines (e.g., IL-1b)
and G protein-coupled receptor agonists (e.g. lipopolysacchride).
The canonical pathway for activation of NF-kB involves
phosphorylation of Ik-Ba by IkBa kinase (IKK2), degradation of
IkBa via the proteasomal pathway, and translocation of NF-kB
dimer to the nucleus. We have examined whether PAR2s are
coupled to activation of NF-kB in smooth muscle cells. Activation
of IKK2 was measured by phosphorylation of IKK2 using
phospho-specific substrate (Ser176/180), IkBa degradation was
measured by western blot and NF-kB activation was measured
by phosphorylation of p65 subunit using phospho-specific
antibody (Ser536). PAR2-AP (1 mM) induced activation of IKK2,
degradation of IkBa and activation of NF-kB in cultured muscle
cells. The effect of PAR2-AP was abolished by treatment of cells
with the RhoA inhibitor (C3 exoenzyme (2 mg/ml)) suggesting that
activation of NF-kB was downstream of RhoA (Fig. 6A)
Feedback inhibition of RhoA by G13-coupled PAR2
Activation of NF-kB pathway by PAR2-AP via RhoA-depen-
dent pathway, and activation of PKA via activation of NF-kB and
regulation of RhoA activity by PKA raised the possibility of
feedback regulation of RhoA/Rho kinase pathway by NF-kB-
dependent mechanism [26]. PAR2-AP-induced Rho kinase
activity was significantly augmented by IKK IV (10 mM), MG-
132 (10 mM) or myristoylated PKI (1 mM) (Fig. 6B). Treatment of
cells with IKK IV (30216486 cpm/mg protein)), MG-132
(28596602 cpm/mg protein), or myristoylated PKI
(32546574 cpm/mg protein) alone had no effect on basal Rho
kinase activity (31256502 cpm/mg protein). The results imply
that feedback inhibition of PAR2-induced Rho kinase is mediated
by PKA. The results also imply that PKA derived from activation
of the canonical NF-kB pathway inhibited RhoA. This notion was
examined by measurements of Rho kinase activity in cells
expressing PKA phosphorylation-site deficient RhoA (S188A) to
block phosphorylation of RhoA by PKA and in cells expressing
dominant negative mutants of IKK2 and IkBa to block activation
of PKA. Rho kinase activity stimulated by PAR2-AP was
augmented in cells expressing RhoA(S188A), IKK2(K44A),and
IkBa (S32A/S36A) (Fig. 6C). The results imply that PAR2-
induced Rho kinase activity was inhibited in a feedback
mechanism via phosphorylation of RhoA at Ser188 by PKA and
the PKA was derived from activation of NF-kB pathway. In
support to this notion treatment of cells with PAR2-AP caused
RhoA phosphorylation, measured in cells metabolically labelled
with 32P, and the effect of PAR2-AP was blocked in cells
expressing phosphorylation-deficient RhoA (S188A) (Fig. 6D).
Further evidence for the release of PKA catalytic subunit from
NF-kB complex in response to PAR2 activation was obtained in
co-immunoprecipitation experiments. In the basal state PKA
catalytic subunit was co-immunoprecipated with NF-kB. Treat-
ment of cells with PAR2-AP attenuated the amount of PKA
catalytic subunit co-immunoprecipitated with NF-kB suggesting
dissociation of the catalytic subunit from NF-kB complex (Fig. 6E).
Figure 3. Inhibition of forskolin-stimulated cAMP formation by
PAR2-AP. Cyclic AMP formation was measured in freshly dispersed
muscle cells in the presence of 100 mM isobutylmethylxanthine. Muscle
cells were treated with PAR2-AP (1 mM) alone, forskolin (FSK, 10 mM)
alone or forskolin plus PAR2-AP (1 mM) for 60 s and cAMP was measured
by radioimmunoassay. In some experiments cells were treated with
pertussis toxin (PTx, 200 ng/ml) for 60 min, and then treated with
forskolin (10 mM) and PAR2-AP (1 mM) for 60 s. Results are expressed as
pmol/mg protein. Values are means 6 S.E. of 4 experiments. **
Significant inhibition of forskolin-stimulated cAMP (P,0.001).
doi:10.1371/journal.pone.0066743.g003
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The effect of PAR2-AP on NF-kB and PKA catalytic subunit
dissociation was blocked in cells transfected with PAR2-specific
siRNA or in cells expressing RhoA(S188A) (Fig. 6E).
Discussion
The gastrointestinal tract, of all the body systems, is exposed to
significant amounts of serine proteases in both normal situations
and during inflammatory bowel diseases. However, expression of
PAR2 receptors and the mechanism underlying their effects on
smooth muscle of the gastrointestinal tract are as yet not
completely understood. Insights into the mechanism of the
PAR2 effects on smooth muscle are important to understand the
underlying mechanism involved in altered muscle contractions
related to inflammatory bowel diseases.
The present study characterized the signaling pathways
mediated by PAR2 in gastric smooth muscle cells using
biochemical, molecular and functional methods. The results
demonstrate the expression of PAR2 in smooth muscle cells and
their ability to cause biphasic contraction and MLC20 phosphor-
ylation. The initial contraction reflected activation of PLC-b via
PTx-sensitive, Gi1 and Gi2, and PTx-insensitive Gq. The sustained
contraction reflected activation of RhoA via G13 and inhibition of
MLC phosphatase via Rho kinase-mediated phosphorylation of
the MLC phosphatase regulatory subunit MYPT1 at Thr696
[19,26,28,29]. Activation of RhoA also results in the stimulation of
the canonical NF-kB pathway and activation of cAMP-indepen-
dent PKA, which, in turn, phosphorylates RhoA at Ser188 and
causes feedback inhibition of RhoA activity (Fig. 7).
The expression of PAR2s in smooth muscle cells of the gut is
consistent with their expression in other cells types of the gut such
as enteric neurons [8], myenteric glia [30], epithelial cells of
intestine and colon [31,32], and endothelial cells and vascular
smooth muscle cells of the gut [33,34]. Studies in various cell lines
Figure 4. Ga13/RhoA-dependent stimulation of Rho kinase activity by PAR2-AP. (A) Freshly dispersed muscle cells were incubated with
PAR2-AP (1 mM) for 10 min and Rho kinase activity was measured by immunokinase assay. Y27632 was used in vitro in the assay to determine the
specificity of Rho kinase activity. (B) Inhibition of PAR2-AP-stimulated Rho kinase activity by dominant negative RhoA (RhoA[T19N]). Cultured smooth
muscle cells expressing dominant negative RhoA (RhoA[T19N]) or vector alone were incubated with PAR2-AP (1 mM) for 10 min. (C) Inhibition of
PAR2-AP-stimulated Rho kinase activity by Ga13 minigene. Cultured gastric muscle cells expressing Ga12 or Ga13 minigene, or control vector were
treated with PAR2-AP (1 mM) for 10 min. Inset: expression of Ga12 and Ga13 in control cells (lane 1), cells transfected with Ga12 minigene (lane 2) or
Ga13 minigene (lane 3) was measured by western blot using antibody to Ga12 (1:1000) or Ga13 (1:1000). (D) Inhibition of PAR2-AP stimulated Rho
kinase activity by PAR2 or Ga13 siRNA. Control muscle cells and cells transfected with PAR2 siRNA or Ga13 siRNA were treated with PAR2-AP (1 mM) for
10 min. Inset: (top panel) expression of PAR2 in control cells (lane 1) and cells transfected with PAR2 siRNA (lane 2) was measured by western blot
using antibody to PAR2 (1:1000); (bottom panel) expression of Ga13 in control cells (lane 1) and cells transfected with Ga13 siRNA (lane 2) was
measured by western blot using antibody to Ga13 (1:1000). Rho kinase activity was measured using [
32P]ATP by immunokinase assay. Results are
expressed as cpm/mg protein. Values are means 6 S.E. of four experiments. ** Significant inhibition from control response (P,0.001).
doi:10.1371/journal.pone.0066743.g004
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suggest that PAR2s are coupled to both PTx-sensitive and PTx–
insensitive G proteins, but the specific G proteins isoforms coupled
to each receptor type have not been characterized [35]. We have
demonstrated that in gastric smooth muscle cells, PAR2 receptors
are coupled to Gi1, Gi2, Gq and G13. PI hydrolysis stimulated by
PAR2 was partially inhibited by suppression of Gaq or by
expression of Gaq or Gai minigene, and additively by co-
expression of Gaq and Gai minigenes suggesting activation of
both Gaq-dependent PLC-b1 and Gbgi-dependent PLC-b3 [36].
In smooth muscle activation of PLC-b1/b3 results in IP3-
dependent Ca2+ release, Ca2+/calmodulin-dependent MLC ki-
nase, phosphorylation of MLC20 and initiation of muscle
contraction [29,36]. Consistent with this scheme, blockade of IP3
generation by PLC-b inhibitor, U73122 or MLC kinase activity by
ML-9 inhibited initial contraction by PAR2.
Rho kinase activity stimulated by PAR2 was inhibited by Ga13
minigene or Ga13 siRNA suggesting activation of Ga13-dependent
activation of RhoA. Activation of RhoA by Gaq, Ga12, or Ga13 is
mediated by various Rho-specific guanine nucleotide exchange
factors (RhoGEFs) that promote exchange of GDP for GTP [37].
The RhoGEF family of proteins includes p115RhoGEF, PDZ-
RhoGEF, and LARG (leukemia-associated RhoGEF). RhoGEF
shares common motifs responsible for binding to activated Ga
subunits and for the exchange of GDP for GTP on RhoA [37].
The involvement of different RhoGEFs in the activation of RhoA
is receptor-specific. For example, in cell lines PAR1-induced
activation of RhoA is mediated by LARG, whereas LPA1-induced
activation of RhoA is mediated by PDZ-RhoGEF [38]. In smooth
muscle activation of PAR2 results in stimulation of Rho kinase
activity and Rho kinase-dependent phosphorylation of MYPT1, a
130-kDa myosin phosphatase targeting subunit that inhibits the
MLC phosphatase activity leading to MLC20 phosphorylation and
muscle contraction. Consistent with this scheme, blockade of Rho
Figure 5. Muscle contraction and phosphorylation of MYPT1 and MLC20 in response to PAR2-AP. (A) Time course of PAR2-AP-induced
contraction in dispersed gastric smooth muscle cells. PAR2-AP (1 mM) was added to freshly isolated muscle cells for different periods of time ranging
from 30 s to 10 min. (B) Concentration-response curves for the contractile effect of PAR2-AP. PAR2-AP was added to freshly isolated muscle cells at a
concentration ranging from 10 pM to 1 mM, and peak contraction at 30 s (solid circles) and sustained contraction at 10 min (solid triangles) were
measured. (C) Phosphorylation of MYPT1, and MLC20 by PAR2-AP in dispersed muscle cells. Freshly dispersed muscle cells were treated with PAR2-AP
for 30 s and 10 min. MLC20 phosphorylation was measured using phospho-specific-Ser
19 MLC20 antibody. MYPT1 phosphorylation was measured
using phospho-specific-Thr696 MYPT1 antibody. (D and E) Effect of inhibitors on initial and sustained contraction in response to PAR2-AP. Freshly
dispersed muscle cells were treated separately with the PLC inhibitor U73122 (10 mM), MLC kinase inhibitor ML-9 (10 mM), PKC inhibitor
bisindolylmaleimide (1 mM), Rho kinase inhibitor Y27632 (1 mM) for 10 min, or pertussis toxin (200 ng/ml) for 60 min, and then treated with PAR2-AP
(1 mM) for 30 s (initial) or 10 min (sustained). Muscle contraction was measured by scanning micrometry, and the results are expressed as percent
decrease in cell length from control cell length (10563 mm). Values are means 6 S.E. of six experiments. ** Significant inhibition from control
response (P,0.001).
doi:10.1371/journal.pone.0066743.g005
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Figure 6. Feedback inhibition of PAR2-AP-stimulated Rho kinase activity by PKA derived from NF-kB pathway. (A) Gastric muscle cells
were incubated with myristoylated PKI for 10 min or with the RhoA inhibitor Clostridium botulinum C3 exoenzyme (2 mg/ml) for 2 h, and then treated
with PAR2-AP for 10 min. Cells were homogenized in lysis buffer and proteins were separated on SDS-PAGE. Phosphorylation (i.e., activation) of IKK2
was measured by western blot phospho-specific (Ser177/181) antibody and phosphorylation of p65 subunit (activation of NF-kB) was measured using
phospho-specific (Ser536) antibody. Degradation of IkBa was measured using antibody to IkBa. Western blot of the b-actin protein is shown for a
control loading. (B) Freshly dispersed gastric smooth muscle cells were treated with PAR2-AP (1 mM) for 10 min in the presence or absence of IKK IV
(10 mM), MG-132 (10 mM), or myristoylated PKI (1 mM). Results are expressed as cpm/mg protein above basal levels (31256502 cpm/mg protein).
Treatment of cells with IKK IV (30216486 cpm/mg protein), MG-132 (28596602 cpm/mg protein), or myristoylated PKI (32546574 cpm/mg protein)
alone had no effect on basal Rho kinase activity. (C) Cultured smooth muscle cells expressing dominant negative mutants of IKK2 (K44A) or IkBa
(S32A/S36A) or the PKA phosphorylation site-deficient RhoA (S188A) were treated with PAR2-AP (1 mM). Rho kinase activity was measured using
[32P]ATP by immunokinase assay. Results are expressed as cpm/mg protein. Values are means 6 S.E. of four experiments. ## Significant increase
from control response to PAR2-AP (P,0.01). (D) Phosphorylation of RhoA was measured in cells labelled with [32P]Pi. Control cells or cells expressing
phosphorylation-site deficient RhoA(S188A) were treated with PAR2-AP (1 mM) and phosphorylation of RhoA was analysed by SDS-PAGE and
autoradiography. (E) Dissociation of PKA catalytic subunit from NF-kB. Control cells, cells transfected with PAR2 siRNA or RhoA(S188A) were treated
with PAR2-AP for 10 min. NF-kB immunoprecipitates were separated by SDS/PAGE and membranes probed with antibodies to the catalytic subunit of
PKA (PKACS, 1:2000) or NF-kB (1:1000).
doi:10.1371/journal.pone.0066743.g006
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kinase activity by Y27632 inhibited sustained contraction in
response to PAR2-AP.
Although PAR2 are coupled to inhibition of cAMP formation,
activation of PAR2 results in the stimulation of cAMP-indepen-
dent protein kinase A (PKA) activity via RhoA-dependent
mechanism involving activation of canonical NF-kB pathways.
The notion that PKA derived from degradation of IkB results in
phosphorylation of RhoA at Ser188 and inhibition of Rho kinase
activity was corroborated using several complimentary approach-
es. We first measured the activation of canonical NF-kB pathway
by PAR2. In the second approach we used IKK2 inhibitor that
blocks IkB phosphorylation and subsequent degradation. In the
third approach we used a proteasomal inhibitor, MG-132 that
prevents degradation of IkB and thus prevents release of PKA
catalytic subunits. In the fourth approach we used the membrane-
permeable specific PKA inhibitory peptide, myristoylated PKI 14-
22 amide. PKI contains PKA pseudosubstrate sequence and
specifically inhibits PKA catalytic subunit by binding to the
substrate-binding site. In the fifth approach we used a dominant
negative mutant IKK2 that lacks the ability to phosphorylate IkB,
a prerequisite for degradation. In the sixth approach we used a
mutant RhoA (S188A) that lacks the PKA phosphorylation site. In
the final approach we measured PAR2-AP-induced dissociation of
NF-kB and PKA catalytic subunit by co-immunoprecipitation
studies.
We concluded that PAR2-stimulated RhoA was inhibited in a
feedback mechanism via cAMP-independent PKA derived from
RhoA-dependent activation of canonical NF-kB pathway based on
the following evidence: i) PAR2-AP induced phosphorylation (i.e
activation) of IKK2, degradation of IkB, and phosphorylation of
p65 subunit of NF-kB (activation of NFkB); ii) PAR2-AP-induced
IKK2 activation, IkB degradation and NF-kB activation was
abolished by a RhoA inhibitor, C3 exoenzyme; iii) PAR2-AP-
stimulated Rho kinase activity was significantly augmented by
PKI, IKK IV or MG132 in freshly dispersed muscle cells and in
cells expressing IKK(K44A), IkBa (S32/S36A) or RhoA(S188A),
and iv) PAR2-AP stimulated dissociation of the PKA catalytic
subunit from NF-kB complex.
Although PAR2s receptors are coupled to Gi and inhibition of
cAMP, they stimulated PKA. The PKA holoenzyme is a
heterotetramer consisting of two catalytic subunits bound to two
regulatory subunits. Classically, the mechanism of PKA activation
in response to cAMP elevating agents (Gs-coupled receptor agonist
or forskolin) involves release of the catalytic subunits upon binding
of two cAMP molecules to each of the regulatory subunit.
Apparently, a certain pool of PKA catalytic subunit is found to be
associated with the NF-kB inhibitor protein, IkB. Recent studies
have identified novel cAMP-independent mechanism for activa-
tion of PKA by various G protein-coupled receptor agonists [39].
The mechanism involves release of PKA catalytic subunit from the
IkB complex upon phosphorylation and degradation of IkB. In the
basal state, a pool of PKA catalytic subunits is maintained in an
inactive state through association with inhibitor of NF-kB (IkB) in
an NF-kB/IkB/PKA (catalytic subunits) complex, and this pool of
PKA is not sensitive to changes in intracellular cAMP levels. IkB
retains the catalytic subunits of PKA in the inactive state,
presumably by masking its ATP binding site, and the signals that
lead to phosphorylation and degradation of IkB, a prerequisite for
NF-kB activation, results in release and activation of the PKA
catalytic subunits. The significance of activation of NF-kB in
response to PAR2 in smooth muscle requires further research.
Smooth muscles respond to inflammatory mediators by synthe-
sizing and secreting various pro- and anti-inflammatory mediators
that, in turn, act in autocrine and paracrine fashion to stimulate
the expression of other cytokines, chemokines, growth factors, and
cell-adhesion molecules [40-42]. The expression of some of these
mediators and regulation of RGS4 expression by cytokines in
smooth muscle are dependent on NF-kB activation [42,43].
Determination of physiological significance of NF-kB activation by
PAR2 may prove significant.
The finding that activation of PKA by a contractile agonist
raises an interesting possibility for regulation of signaling molecules
involved in the contractile pathway by PKA. It is well established
that activation of PKA in gastric smooth muscle cells inhibits
muscle contraction, resulting from decrease in [Ca2+]i and MLC20
phosphorylation. These effects of PKA are a consequence of the
inhibitory action of PKA on multiple components of the Gaq/
Ga13 signaling culminating in muscle relaxation.
In conclusion, our studies have demonstrated the expression of
PAR2 in smooth muscle and identified the receptor-specific signal
transduction pathways in mediating smooth muscle contraction. In
gastric smooth muscle cells PAR2 are coupled to activation of Gq,
G13, Gi1, and Gi2, but not Gi3, G12, Gs, and stimulation of PI
hydrolysis via both Gaq and Gbgi. PAR2 are coupled to activation
of RhoA/Rho kinase via Ga13. PAR2 induced initial contraction
was mediated by stimulation of PLC-b activity, generation of IP3,
IP3-dependent Ca
2+ release, Ca2+/calmodulin-dependent activa-
tion of MLC kinase and phosphorylation of MLC20 at Ser
19.
Whereas sustained contraction was mediated by sequential
activation of G13, RhoA and Rho kinase, and Rho kinase-
dependent phosphorylation of MYPT1 at Thr696 and inhibition of
MLC phosphatase. Although PAR2s are coupled to inhibition of
cAMP, they stimulated cAMP-independent PKA activity via
RhoA-dependent canonical NF-kB pathway and this resulted in
feedback inhibition of Rho kinase activity via inhibitory phos-
phorylation of RhoA at Ser188.
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Figure 7. Signaling by PAR2 in smooth muscle. In gastric smooth
muscle PAR2 receptors are coupled to Gq, G13 and Gi1/2, and stimulation
of PI hydrolysis via Gaq and Gbgi1/2, and RhoA/Rho kinase via Ga13.
Initial contraction is mediated via PLC-b/Ca2+/MLCK pathway whereas
sustained contraction is mediated via RhoA/Rho kinase pathway.
Although PAR2 receptors are coupled to inhibition of cAMP via Ga i1/
2, activation of NF-kB pathway via Ga13/RhoA leads to degradation of
IkB and activation of PKA that result in attenuation of Rho kinase
activity in a feedback mechanism via phosphorylation of RhoA at Ser188
by PKA.
doi:10.1371/journal.pone.0066743.g007
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